CVS Health Trades Cheaper Than Industry: How to Play the Stock?

CVS Health (CVS) is currently viewed as attractively valued, with a forward five-year price-to-sales ratio of 0.23, significantly below its industry and peers, contributing to a 64.2% year-to-date stock surge. This strong performance is underpinned by its diversified model, including progress in stabilizing Aetna's Medicare business and rationalizing ACA plans, alongside strength in the Pharmacy & Consumer Wellness segment driven by the new CostVantage reimbursement model. Furthermore, CVS is investing $20 billion over the next decade in a digital-first strategy to enhance healthcare interoperability and consumer experience, leading to improving earnings estimates and a favorable investment outlook.

Analysis

CVS Health is demonstrating strong operational momentum and presents an attractive valuation profile. The stock's forward five-year price-to-sales ratio stands at 0.23, a significant discount to its historical median of 0.29, the industry average of 0.41, and peers such as UnitedHealth Group (0.61). This valuation has been coupled with robust market performance, with the stock surging 64.2% year-to-date. Growth is underpinned by a diversified model, notably the stabilization of its Aetna insurance arm, which is showing year-over-year gains in Medicare and strategically exiting underperforming ACA markets. The Pharmacy & Consumer Wellness segment is mitigating reimbursement pressures through the new CostVantage model, which is now applied to 100% of commercial scripts. Furthermore, CVS is executing a long-term digital strategy, underscored by a $20 billion, decade-long commitment to create a tech-enabled, interoperable health ecosystem. This positive operational narrative is reflected in upwardly revised earnings estimates, with the 2025 EPS consensus rising 3.9% in the past 90 days to $6.34, suggesting a nearly 17% increase over 2024.

Key Decisions for Investors

• Given the forward P/S ratio of 0.23 remains well below peer valuations and historical norms despite a 64.2% year-to-date rally, investors may consider the stock to still hold relative value.
• Investors should closely monitor the margin impact and adoption progress of the new CostVantage model within the Pharmacy & Consumer Wellness segment, as its success is a key catalyst for offsetting industry-wide reimbursement pressures.
• The stabilization of the Aetna insurance arm and the execution of the $20 billion digital transformation plan are critical long-term growth drivers; progress on these initiatives should be a primary focus in upcoming earnings calls and company reports.
• With analysts having revised 2025 and 2026 EPS estimates upward by 3.9% and 2.3% respectively in the last 90 days, it is prudent to watch for continued fundamental performance to support this heightened market expectation.